Blunt End 5′ Triphosphate Oligonucleotide RIG-I Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective agents for specifically activating RIG-I and inducing an anti-viral, particularly IFN, response in cells, and there is a need for alternative approaches to treat infections, tumors, and immune disorders by enhancing immunogenicity and inducing apoptosis in tumor cells.
Innovation Solution
Development of oligonucleotides with specific structural motifs, such as a blunt end with a 5' triphosphate, that activate RIG-I and have gene-silencing activity, capable of inducing type I IFN production and apoptosis in tumor cells, used in combination with other immunostimulatory agents for treating infections and tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oligonucleotides with 5' triphosphate and blunt end structures are designed to activate RIG-I, then the ability to induce anti-viral response and apoptosis is improved, but the complexity of oligonucleotide synthesis and purification increases
Solution Approach 1:
The patent applies parameter changes by precisely controlling the chemical structure parameters of the oligonucleotide, specifically introducing a 5' triphosphate group and blunt end configuration. These structural parameter modifications enable RIG-I activation while maintaining sequence-specific gene silencing capability, thus improving reliability without requiring complex synthesis procedures
Solution Approach 2:
The oligonucleotide design achieves multi-functionality by combining gene silencing activity (through sequence complementarity to target mRNA) with immunostimulatory activity (through 5' triphosphate blunt end structure that activates RIG-I). This universal design allows a single oligonucleotide to perform both therapeutic gene silencing and immune activation functions
2Reliability
If oligonucleotides are designed to have both gene-silencing activity and RIG-I activation capability, then the therapeutic effectiveness against tumors and infections is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent employs parameter changes by establishing specific structural parameters for the oligonucleotide: a blunt end configuration with a 5' triphosphate group and a double-stranded region of at least 19 base pairs. These precisely defined parameters ensure both gene silencing specificity and RIG-I activation capability, improving therapeutic effectiveness while providing clear manufacturing specifications
Solution Approach 2:
The invention applies local quality by creating distinct functional regions within the oligonucleotide structure: the 5' triphosphate blunt end region provides immunostimulatory activity for RIG-I activation, while the complementary base-pairing region provides gene silencing activity. Each region has optimized local properties that contribute to the overall therapeutic effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligonucleotides effectively activate RIG-I, induce type I IFN production, and enhance immunogenicity, leading to improved treatment outcomes for infections, tumors, and immune disorders by targeting specific molecular signatures and promoting apoptosis in tumor cells.
Implementation Method 1
The present invention provides an oligonucleotide which is capable of activating RIG-I and/or inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I
Implementation Method 2
capable of inducing type I IFN production and apoptosis in tumor cells
Data Source
AI summary
The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5′ triphosphate, and at least one blunt end which bears a 5′ triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.